PLIANT THERAPEUTICS, INC. Operating Income Loss

Quick Answer

PLIANT THERAPEUTICS, INC. reported Operating Income Loss of -$156.37 million for the year ending 2025.

  • PLIANT THERAPEUTICS, INC. showed an increase of +31.5% in Operating Income Loss from 2024 to 2025.
  • This data is from PLIANT THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), PLIANT THERAPEUTICS, INC.'s Operating Income Loss has declined by 12,602.9%.
  • Historical annual values: Fiscal year 2025: -$156.37 million | Fiscal year 2024: -$228.37 million | Fiscal year 2023: -$184.15 million | Fiscal year 2022: -$127.20 million | Fiscal year 2021: -$97.54 million | Fiscal year 2020: -$41.65 million | Fiscal year 2019: -$1.23 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: